Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.

Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.

Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.

The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.